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Abstract
Background: Local‐regional failure (LF) for locally advanced bladder cancer 
(LABC) after radical cystectomy (RC) is common even with chemotherapy and is 
associated with high morbidity/mortality. Postoperative radiotherapy (PORT) can 
reduce LF and may enhance overall survival (OS) but has no defined role. We hy-
pothesized that the addition of PORT would improve OS in LABC in a large nation-
wide oncology database.
Methods: We identified ≥ pT3pN0‐3M0 LABC patients in the National Cancer 
Database diagnosed 2004‐2014 who underwent RC ± PORT. OS was calculated 
using Kaplan‐Meier and Cox proportional hazards regression modeling was used to 
identify predictors of OS. Propensity matching was performed to match RC patients 
who received PORT vs those who did not.
Results: 15,124 RC patients were identified with 512 (3.3%) receiving PORT. 
Median OS was 20.0 months (95% CI, 18.2‐21.8) for PORT vs 20.8 months (95% CI, 
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1 |  INTRODUCTION
Local‐regional failure (LF) for locally advanced bladder can-
cer (LABC) after radical cystectomy (RC) is common, and 
is associated with high morbidity and mortality.1-3 Adjuvant 
chemotherapy has not been shown in randomized prospec-
tive trials to reduce the risk of LFs,1,4 and salvage strategies 
after LF are rarely successful.2,5,6 Postoperative radiotherapy 
(PORT) has been shown to significantly reduce local failures 
and may enhance survival.7,8 A recently published phase II 
randomized trial in Egypt of patients with LABC status post 
RC and pelvic lymph node dissection with negative margins 
reported significantly improved local control with the addi-
tion of PORT vs adjuvant chemotherapy alone, with 2‐year 
local control of 96% for sequential chemotherapy plus PORT 
vs 69% for chemotherapy alone (P < 0.01).8 Disease‐free 
survival and overall survival (OS) were improved with the 
addition of PORT but the study was not powered for those 
endpoints. While only 53% of the patients had urothelial car-
cinoma, outcomes did not differ based on histology.
Interest in PORT after RC has increased in Europe and 
North America, and researchers have identified an externally 
validated risk stratification for selecting patients at highest 
risk for local failure who are most likely to benefit from 
PORT and have mapped the patterns of failure in the pelvis to 
design consensus target volumes.1,9-13 An NRG randomized 
phase II trial of PORT vs no PORT (NRG‐GU001) opened 
in 2015 in the US and Canada but closed early due to poor 
accrual. Other trials of PORT in Europe, India, and Egypt 
have opened, but are not powered for an OS endpoint.14 It 
is unlikely that a randomized trial of sufficient size can be 
conducted in the West to assess whether PORT improves 
OS, and large retrospective series are lacking. The purpose 
of this study is to investigate whether the addition of PORT 
improved OS using the National Cancer Database (NCDB), a 
database of sufficient size to potentially answer the question. 
We hypothesized that the addition of PORT would improve 
overall survival in patients with LABC.
2 |  MATERIALS AND METHODS
2.1 | Study population
The NCDB Participant User File for bladder tumors was re-
viewed to identify all patients 18‐90 years old diagnosed with 
bladder cancer from 2004 to 2014. Data from approximately 
70% of the patients diagnosed at Commission on Cancer‐ac-
credited cancer centers is incorporated and includes patient, 
tumor, and treatment characteristics. The Participant User 
File contains de‐identified patient and center information and 
was exempt from Institutional Review Board review.
From this dataset, we selected a cohort of patients who 
would have been eligible for the NRG‐GU001 study as fol-
lows. All patients included received cystectomy as defined 
by cystectomy, RC, or more advanced surgical procedure 
(ie, exenteration). Only patients with pT3‐4,N0‐3,M0 dis-
ease, known surgical margin status, nonsmall cell and non-
lymphoma histology, and known chemotherapy details were 
included. Additionally, those patients who died within 30 
days of surgery or did not have follow‐up information were 
excluded. Lastly, patients with more favorable disease char-
acteristics (pT3a,N0 and ≥ 10 LN dissected, and negative 
surgical margins) were excluded as these patients have been 
shown to have lower risk of LF and were excluded from 
20.3‐21.3) for no PORT (P = 0.178). In multivariable analysis, PORT was indepen-
dently associated with improved OS: hazard ratio 0.87 (95% CI, 0.78‐0.97); P = 0.008. 
A one‐to‐three propensity match yielded 1,858 patients (24.9% receiving PORT and 
75.1% without). In the propensity‐matched cohort, median OS was 19.8 months (95% 
CI, 18.0‐21.6) for PORT vs 16.9 months (95% CI, 15.6‐18.1) for no PORT 
(P = 0.030). In the propensity‐matched cohort of urothelial carcinoma patients 
(N = 1,460), PORT was associated with improved OS for pT4, pN+, and positive 
margins (P < 0.01 all).
Conclusion: In this observational cohort, PORT was associated with improved OS in 
LABC. While the data should be interpreted cautiously, these results lend support to 
the use of PORT in selected patients with LABC, regardless of histology. Prospective 
trials of PORT are warranted.
K E Y W O R D S
adjuvant radiation therapy, bladder cancer, PORT
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NRG‐GU001.10 Patients were classified into two cohorts: 
postoperative radiotherapy (PORT) vs no PORT. Patients in-
cluded in the PORT cohort received postoperative external 
beam radiotherapy to the pelvis/cystectomy bed within 1 year 
of surgery to a total dose of ≥ 40 Gy. Patients receiving pal-
liative pelvic radiation therapy as coded by the NCDB were 
excluded. Patients who died within 30 days of surgery were 
excluded. Patient CONSORT diagram detailing complete in-
clusion criteria is found in Figure S1.
Patient characteristics for analysis included: age, sex, race, 
Charlson‐Deyo comorbidity index (CCI), treatment facility 
type, primary insurance status, histology, pathologic T‐stage, 
pathologic N‐stage, number of regional nodes examined, sur-
gical margin status, receipt of chemotherapy (both neoadju-
vant and adjuvant), and receipt of radiotherapy. The primary 
endpoint was overall survival.
2.2 | Statistical analysis
The chi‐squared test was used to compare categorical demo-
graphic and patient characteristics between the two treatment 
groups. The Student's t test was used to compare continuous 
variables between groups. Overall survival was calculated 
from diagnosis until death, censoring at last follow‐up for 
patients who were alive. The Kaplan‐Meier method was used 
to estimate overall survival probabilities. Univariable (UVA) 
and multivariable analysis (MVA) logistic regression mod-
eling were used to identify predictors of receiving adjuvant 
radiotherapy and are reported as odds ratios. UVA and MVA 
Cox proportional hazard modeling were used to identify fac-
tors associated with overall survival and are reported as haz-
ard ratios (HR) with corresponding 95% confidence intervals. 
The MVA models were created by including all covariates 
and then removing each covariate with a P value > 0.2 in 
a step‐wise method. Categorical covariates were included in 
the final model if the covariate levels in comparison with the 
reference group had a P value < 0.1.15 To confirm appropri-
ate selection of predictive variables entered into multivaria-
ble analysis, a stepwise regression was utilized. Proportional 
hazards assumptions were tested using Schoenfeld residuals 
tests and were not violated. P < 0.05 was considered signifi-
cant. All were two‐sided.
Since observational studies are susceptible to unmeasured 
confounding, we conducted a regression‐based sensitivity 
analysis in which we evaluated the sensitivity of our Cox 
HR to the presence of a binary confounder (such as patient 
functional status which was not available in our dataset). We 
varied the prevalence and strength of the unmeasured con-
founder to assess whether our primary findings would be al-
tered if in fact we could have adjusted for the unmeasured 
confounder.16
A secondary propensity score (PS) matched analysis 
was conducted to better potentially account for differences 
in baseline patient characteristics between the PORT and no 
PORT groups. Matching was performed based on patient 
characteristics and disease factors that included: age, sex, 
race, CCI, facility type, insurance status, histology, patho-
logic T‐stage, pathologic N‐stage, margin status, number of 
nodes examined, and chemotherapy treatment information 
including neoadjuvant vs adjuvant. One‐to‐three matching 
using nearest‐neighbor algorithm assuming independent ob-
servations and fixed weights was performed. Caliper width 
was narrowed in a stepwise fashion until the covariate dis-
tributions were balanced after matching.17 A caliper width 
of 0.2 was used in subsequent analyses. Balancing of groups 
after PS matching was verified using the χ2 test for categor-
ical variables and the t test for continuous variables as well 
as comparing standardized differences of baseline covariates 
between the PORT and no PORT groups. After matching, a 
matched‐sample UVA Cox regression model was applied to 
the matched groups to estimate the effect of treatment on sur-
vival.18 Forest plots were generated after PS matching using 
UVA Cox regression to analyze the subgroup interactions. 
SPSS Statistics v.23 (IBM Corporation; Armonk, NY) was 
used for all statistical analyses.
3 |  RESULTS
3.1 | Demographics and factors associated 
with receipt of PORT
Of the 484,367 patients diagnosed with bladder cancer from 
2004 to 2014 in the NCDB, we identified 15,124 patients 
who met inclusion criteria (Figure S1). Median follow‐up 
was 18.8 months (25‐75th quartile: 9.8‐39.0 months). Five 
hundred and twelve (3.3%) of the patients received PORT. 
Median time from surgery to PORT was 110 days [25‐75th 
quartile: 52‐188 days]. Median radiation dose was 50.4 Gy 
[25‐75th quartile: 45‐55.80 Gy]. Median age of patients 
receiving PORT was 65 years vs 69 years for no PORT 
(P < 0.0001). Baseline patient characteristics are listed in 
Table 1. Multivariable logistic regression showed that cofac-
tors associated with increased likelihood for PORT included: 
female gender, nonurothelial histology, pathologic T4 stage, 
positive surgical margins, and receipt of chemotherapy 
(Table 2).
3.2 | Survival analysis
The median follow‐up for patients receiving PORT was 
18.6 months vs 18.8 months in the no PORT group. The me-
dian OS was 20.0 months (95% CI, 18.2‐21.8) for the PORT 
group vs 20.8 months (95% CI, 20.3‐21.3) for the group that 
did not receive PORT (P = 0.178) (Figure S2). For patients 
with pT4 disease, the median OS was 17.9 months (95% CI, 
16.3‐19.6) for PORT vs 15.9 months (95% CI, 15.2‐16.5) 
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N 14,612 (96.7%) 512 (3.3%)  
Age, years   <0.0001
Mean 68.0 64.6  
SD 10.6 10.8  
Median 69 65  
Range 22‐90 32‐90  
Sex
Male 10,583 (72.4%) 319 (62.3%) <0.0001
Female 4,029 (27.6%) 193 (37.7%)  
Race
White 13,240 (90.6%) 452 (88.3%) 0.074
Other 1,372 (9.4%) 60 (11.7%)  
Charlson‐Deyo Comorbidity:
0 10,228 (70.0%) 375 (73.2%) 0.247
1 3,328 (22.8%) 101 (19.7%)  
≥2 1,056 (7.2%) 36 (7.0%)  
Facility Type
Academic/Research Program 7,248 (49.6%) 157 (30.7%) <0.0001
Other 7,263 (49.7%) 346 (67.6%)  
Unknown 101 (0.7%) 9 (1.8%)  
Insurance Status
Private 4,470 (30.6%) 185 (36.1%) 0.004
Other 10,142 (69.4%) 327 (63.9%)  
Histology
Urothelial 12,972 (88.8%) 389 (76.0%) <0.0001
Squamous 860 (5.9%) 69 (13.5%)  
Adeno 271 (1.9%) 22 (4.3%)  
Other (excluding small cell/lymphoma) 509 (3.5%) 32 (6.3%)  
Pathologic T‐stage
T3 9,729 (66.6%) 219 (42.8%) <0.0001
T4 4,883 (33.4%) 293 (57.2%)  
Positive Lymph Nodes
No 7,678 (52.5%) 258 (50.4%) 0.345
Yes 6,934 (47.5%) 254 (49.6%)  
Number of Regional Lymph Nodes Examined
Mean 12.9 10.3 0.946
SD 12.3 10.2  
Median 9.0 8.0  
Range 0‐90 0‐62  
Positive surgical margins
No 11,707 (80.1%) 249 (48.6%) <0.0001
Yes 2,905 (19.9%) 263 (51.4%)  
Chemotherapy
(Continues)
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for no PORT (P = 0.232) (Figure 1A). Patients with node‐
positive disease had a median OS of 20.1 months (95% CI, 
17.1‐23.2) for PORT vs 17.0 (95% CI, 16.5‐17.5) for no 
PORT (P = 0.133) (Figure 1B). For patients with positive 
surgical margins, the median OS was 17.9 months (95% CI, 
15.6‐20.1) for PORT vs 12.8 months (95% CI, 12.2‐13.4) 
for no PORT (P < 0.0001) (Figure 1C). For patients with 
both pT4 disease and positive surgical margins, the me-
dian OS was 17.3 months (95% CI, 15.8‐18.8) for PORT vs 
11.7 months (95% CI, 11.1‐12.2) for no PORT (P < 0.0001) 
(Figure 1D). In multivariable analysis, PORT was indepen-
dently associated with an improved OS (HR: 0.87 [95% CI, 
0.78‐0.97]; P = 0.008) (Table 3).
3.3 | Sensitivity analysis
We performed a sensitivity analysis to assess the potential 
effect of unmeasured confounding on the primary outcome 
of overall survival. We chose patient functional status, which 
was not available to us in this study, although the analy-
sis would apply to other unmeasured confounders, such as 
smoking status. Our sensitivity analysis showed that if there 
was an unmeasured confounder with a deleterious effect on 
OS with a HR of 1.25 and was 9% more common in the no 
PORT cohort, adjusting for it would not change the overall 
findings that PORT is associated with significantly improved 
OS (updated HR 0.90, 95% CI 0.80‐0.99). If the prevalence 
of the deleterious unmeasured confounder in the control 
group was much greater, for example 20% higher, PORT 
would no longer be statistically significant (HR 0.90, 95% 
CI 0.85‐1.04).
3.4 | Matched analysis
A one‐to‐three propensity match yielded a total of 1,858 pa-
tients (24.9% receiving PORT and 75.1% without receipt of 
PORT) (Table S1). In the propensity‐matched cohort, median 
OS was 19.8 months (95% CI, 18.0‐21.6) for the PORT group 
vs 16.9 months (95% CI, 15.6‐18.1) for the group that did not 
receive PORT (log‐rank P = 0.030, Wilcoxon P < 0.0001, 
Tarone‐Ware P < 0.0001) (Figure 2A). For patients with pT4 
disease, the median OS was 17.9 months (95% CI, 16.2‐19.4) 
for PORT vs 13.2 months (95% CI, 12.2‐14.3) for no PORT 
(P = 0.003) (Figure 2B). For patients with node‐positive dis-
ease, the median OS was 20.2 months (95% CI, 17.4‐23.0) for 
PORT vs 15.1 (95% CI, 13.7‐16.4) for no PORT (P = 0.003) 
(Figure 2C). For patients with positive surgical margins, the 
median OS was 17.8 months (95% CI, 15.8‐19.8) for PORT 
vs 12.4 months (95% CI, 11.5‐13.2) for no PORT (P = 0.002) 
(Figure 2D). For patients with both pT4 disease and positive 
surgical margins, the median OS was 17.2 months (95% CI, 
15.8‐18.6) for PORT vs 11.9 months (95% CI, 11.0‐12.7) 
for no PORT (P < 0.0001) (Figure 2E). PORT was indepen-
dently associated with improved OS in the matched cohort 
(HR: 0.88 [95% CI, 0.77‐0.98]; P = 0.030). A forest plot of 
tumor and treatment characteristics and their association with 
OS is depicted in Figure 3.
3.5 | Urothelial cohort
From the propensity‐matched cohort, 1,460 patients with 
urothelial histology were identified. Three hundred and 
fifty‐seven (24.5%) patients in this subgroup received 
PORT and 1,103 (75.5%) patients did not receive PORT. 
Other patient characteristics and receipt of chemotherapy in 
the urothelial cohort were well balanced (data not shown). 
Median OS was 20.2 months (95% CI, 18.2‐22.3) for the 
patients that received PORT compared to 17.2 months (95% 
CI, 15.8‐18.2) for no PORT (P = 0.099). For urothelial pa-
tients with pT4 disease, the median OS was 18.6 months 
(95% CI, 16.4‐20.8) for PORT vs 13.6 months (95% CI, 




None 8,329 (57.0%) 119 (23.2%) <0.0001
Single‐agent 474 (3.2%) 98 (19.1%)  
Multi‐agent 5,382 (36.8%) 263 (51.4%)  
Number of agents unknown 428 (2.9%) 32 (6.3%)  
Chemotherapy Sequence   <0.0001
None 8,201 (56.1%) 118 (23.0%)  
Neoadjuvant 1,405 (9.6%) 48 (9.4%)  
Adjuvant 4,311 (29.5%) 311 (60.7%)  
Both 415 (2.8%) 23 (4.5%)  
Unknown 280 (1.9%) 12 (2.3%)  
T A B L E  1  (Continued)
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patients with node‐positive disease, the median OS was 
20.7 months (95% CI, 17.8‐23.6) for PORT vs 15.3 (95% 
CI, 13.8‐16.9) for no PORT (P = 0.011) (Figure S3B). For 
patients with positive surgical margins, the median OS was 
18.3 months (95% CI, 15.9‐20.7) for PORT vs 12.9 months 
(95% CI, 11.6‐14.3) for no PORT (P = 0.002) (Figure 
T A B L E  2  Univariable and multivariable logistic regression for receipt of adjuvant RT
 
Univariate Multivariate
Odds ratio P‐Value Odds ratio P‐Value
Age
Years 0.97 (0.96‐0.98) <0.0001 0.98 (0.97‐0.99) 0.003
Sex
Male Reference Group  Reference Group  
Female 1.57 (1.31‐1.89) <0.0001 1.47 (1.20‐1.80) <0.0001
Race
White Reference Group  Reference Group  
Other 0.79 (0.60‐1.04) 0.095 0.82 (0.61‐1.11) 0.201
Charlson‐Deyo Comorbidity:
0 Reference Group  Reference Group  
1 0.83 (0.66‐1.04) 0.109 0.93 (0.73‐1.18) 0.456
≥2 0.93 (0.63‐1.29) 0.558 1.12 (0.77‐1.63) 0.434
Facility Type
Academic/Research Program 0.45 (0.37‐0.55) <0.0001 0.48 (0.39‐0.60) <0.0001
Other Reference Group  Reference Group  
Unknown 1.92 (0.96‐3.82) 0.075 0.91 (0.41‐2.03) 0.816
Insurance Status
Private Insurance 1.29 (1.07‐1.56) 0.008 1.03 (0.82‐1.29) 0.790
Other Reference Group  Reference Group  
Histology
Urothelial Reference Group  Reference Group  
Squamous 2.70 (2.07‐3.53) <0.0001 2.65 (1.96‐3.60) <0.0001
Adeno 2.51 (1.58‐4.00) <0.0001 2.07 (1.24‐3.44) 0.005
Other (excluding small cell/
lymphoma)
2.15 (1.49‐3.12) <0.0001 1.59 (1.06‐2.39) 0.025
Pathologic T‐stage
T3 Reference Group  Reference Group  
T4 2.84 (2.37‐3.40) <0.0001 2.04 (1.67‐2.49) <0.0001
Positive Lymph Nodes
No Reference Group  Reference Group  
Yes 1.15 (0.96‐1.38) 0.125 0.90 (0.74‐1.10) 0.290
Number of Regional Lymph 
Nodes Examined
0.98 (0.97‐0.99) <0.0001 0.98 (0.97‐0.99) <0.0001
Positive Surgical Margins
No Reference Group  Reference Group  
Yes 4.50 (3.75‐5.39) <0.0001 3.31 (2.71‐4.03) <0.0001
Chemotherapy
None Reference Group  Reference Group  
Single‐agent 5.19 (3.45‐7.80) <0.0001 4.66 (3.03‐7.17) <0.0001
Multi‐agent 14.12 (10.6‐18.8) <0.0001 11.66 (8.52‐15.9) <0.0001
Number of agents unknown 3.44 (2.76‐4.29) <0.0001 3.27 (2.57‐4.17) <0.0001
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S3C). For patients with both pT4 disease and positive sur-
gical margins, the median OS was 17.4 months (95% CI, 
15.7‐19.1) for PORT vs 11.9 months (95% CI, 10.9‐12.9) 
for no PORT (P = 0.002) (Figure S3D).
4 |  DISCUSSION
Local‐regional failure for LABC after RC is common. In both 
SWOG 8710 and Medical Research Council trials of RC with 
or without neoadjuvant chemotherapy, the 5‐year incidence 
of LFs for patients with ≥ pT3 urothelial carcinoma was over 
30%.1,4 It has been hypothesized that reducing LFs may lead 
to improved disease‐free and overall survival. From a surgi-
cal perspective, retrospective series have associated more ex-
tensive nodal dissections with improved survival outcomes, 
even in the absence of nodal metastasis, which suggests that 
removal of occult nodal disease may improve survival by de-
creasing LFs.19 Additionally, there is an evidence that local 
failure often precedes but uncommonly follows the develop-
ment of distant metastasis, suggesting that local failure may 
seed distant disease.20 Even if LF did not reduce the risk of 
DM or affect survival, there is often considerable morbidity 
associated with LF and efforts to reduce LF may improve 
patient quality‐of‐life.2
Given the association between LF and development of 
distant disease, methods to improve local control may be 
warranted and may improve survival. While the addition of 
chemotherapy to RC improves overall survival, it has not 
been shown in randomized prospective trials to reduce the 
risk of LF.1,4 As improvements in systemic therapy further re-
duce the risk of distant disease, treatments designed to reduce 
local recurrences will gain in importance to reduce the over-
all risk of relapse. Additionally, salvage strategies after LF 
are rarely successful with a median survival of approximately 
9 months.21,22 PORT for LABC thus offers an option to sig-
nificantly improve local control, which may in turn improve 
survival, but the role of PORT has not been clearly defined.
F I G U R E  1  Kaplan‐Meier overall survival curves for PORT vs no PORT in: (A) pathologic T4 (pT4) disease; (B) node positive disease; 
(C) positive surgical margins; (D) both pT4 disease and positive surgical margins. PORT, postoperative radiotherapy. Green line = PORT, Blue 
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T A B L E  3  Univariable and multivariable Cox regression for overall survival
 
Univariable Multivariable
Hazard ratio P‐Value Hazard ratio P‐Value
Postoperative RT 
(PORT)
1.09 (0.98‐1.21) 0.101 0.87 (0.78‐0.97) 0.008
Age
Years 1.01 (1.01‐1.02) <0.0001 1.01 (1.01‐1.01) <0.0001
Sex
Male Reference Group  Reference Group  
Female 1.05 (1.01‐1.10) 0.013 1.03 (0.99‐1.08) 0.124
Race
White Reference Group  Reference Group  
Other 0.94 (0.89‐1.01) 0.077 0.92 (0.86‐0.98) 0.009
Charlson‐Deyo Comorbidity
0 Reference Group  Reference Group  
1 1.21 (1.16‐1.27) <0.0001 1.17 (1.12‐1.22) <0.0001




0.95 (0.92‐0.99) 0.013 0.96 (0.93‐1.00) 0.060
Other Reference Group  Reference Group  
Unknown 0.86 (0.68‐1.08) 0.199 1.24 (0.98‐1.58) 0.078
Insurance Status
Private Insurance 0.78 (0.75‐0.81) <0.0001 0.91 (0.87‐0.96) <0.0001
Other Reference Group  Reference Group  
Histology
Urothelial Reference Group  Reference Group  
Squamous 1.12 (1.07‐1.25) <0.0001 1.18 (1.09‐1.28) <0.0001
Adeno 0.89 (0.77‐1.02) 0.090 0.82 (0.72‐0.95) 0.008
Other (excluding small 
cell/lymphoma)
1.22 (1.10‐1.34) <0.0001 1.12 (1.01‐1.24) 0.025
Pathologic T‐stage
T3 Reference Group  Reference Group  
T3a 1.04 (0.97‐1.12) 0.230 0.98 (0.91‐1.05) 0.616
T3b 1.18 (1.10‐1.27) <0.0001 1.21 (1.13‐1.31) <0.0001
T4 1.52 (1.37‐1.67) <0.0001 1.37 (1.27‐1.52) <0.0001
T4a 1.44 (1.34‐1.54) <0.0001 1.36 (1.27‐1.48) <0.0001
T4b 2.21 (1.98‐2.47) <0.0001 2.02 (1.80‐2.27) <0.0001
Positive Lymph Nodes
No Reference Group  Reference Group  
Yes 1.45 (1.45‐1.57) <0.0001 1.79 (1.72‐1.87) <0.0001
Number of Regional 
Lymph Nodes 
Examined
0.99 (0.99‐0.99) <0.0001 0.99 (0.99‐0.99) <0.0001
Positive surgical margins
No Reference Group  Reference Group  
Yes 1.68 (1.60‐1.75) <0.0001 1.51 (1.44‐1.59) <0.0001
(Continues)
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Concerns for significant toxicity after PORT have been 
a major reason why adoption of this adjuvant therapy has 
been rather limited. Toxicity results using outdated radio-
therapy techniques in the 1970s and 1980s did show rel-
atively high rates of toxicity. However, the results of the 
Zaghloul et al trial of post‐operative radiotherapy plus ad-
juvant chemotherapy vs adjuvant chemotherapy alone after 
RC that used more modern three‐dimensional conformal ra-
diotherapy reported low rates of late GI toxicity for PORT.8 
In addition, a patterns of failure analysis by Baumann et al 
demonstrated that the cystectomy bed could be safely omit-
ted for patients with negative margins, thus significantly 
reducing the amount of radiation dose to the central pelvis 
since only the pelvic side wall nodes would have to be cov-
ered to full dose.9 The radiation target volumes for PORT 
in patients with negative margins are routinely smaller than 
those commonly used for patients with prostate cancer re-
ceiving postoperative whole pelvis radiotherapy.
The use of PORT vs no PORT following RC in patients 
with LABC has not been evaluated in large, modern phase 
III trials powered to detect a benefit in overall survival. A 
previous randomized clinical trial of adjuvant RT vs ob-
servation conducted in the 1980s at the National Cancer 
Institute in Cairo, Egypt reported a significant improve-
ment in both local control and disease‐free survival with 
PORT.7 In that study, 80% of the patients had squamous 
cell carcinoma and only 20% had urothelial carcinoma but 
the outcomes were equivalent independent of histology. 
That trial, which used older two‐dimensional RT tech-
niques, established PORT as a standard adjuvant treatment 
for LABC in Egypt. A second randomized trial conducted 
at the NCI in Cairo compared sequential PORT and chemo-
therapy (n = 75) vs adjuvant chemotherapy alone (n = 45) 
in patients with LABC who had complete (R0) resections 
and again confirmed a significant benefit in local control.8 
DFS and OS were improved but the study was not powered 
for those endpoints and the differences were not signifi-
cant. In that trial, 53% of the patients had urothelial carci-
noma, which may make these results more applicable to a 
western patient population. In an unplanned subset analysis 
of patients with urothelial carcinoma, the addition of PORT 
was also associated with a statistically significant improve-
ment in local control.8
Interest in PORT has grown outside of Egypt and the Middle 
East, 23 and several trials of adjuvant RT have opened recently, 
including a cooperative group trial in France (GETUG) and 
single‐institution trials at Tata Memorial Hospital (Mumbai, 
India) and Ghent University (Ghent, Belgium).14,24 The NRG 
Oncology cooperative group opened a trial in 2015 to eval-
uate the benefit of PORT for LABC that enrolled patients 
with pT3‐4 N0‐2 M0 bladder cancer after RC (NRG‐GU001). 
Unfortunately, the trial closed in 2017 due to poor accrual 
with insufficient patient numbers for analysis.
Given the closure of NRG‐GU001 and the challenges of 
accruing patients on trials of PORT in Europe and North 
America, it is unlikely that a phase III trial powered to detect 
an overall survival difference could be successfully completed 
in the near future. Therefore, we are limited to retrospective 
analyses of large population‐based databases. Fortunately, 
the selection criteria for patients who are most likely to ben-
efit from PORT has been developed and externally validated 
and this information was incorporated in the selection criteria 
for NRG‐GU001.1,10,25,26 In this study, we identified a patient 
population similar to the inclusion criteria for NRG‐GU001 
and evaluated the role of PORT in this patient population.
We found that PORT was independently associated with 
an overall survival benefit on multivariable analysis. While 
important prognostic covariates such as age, T‐stage, positive 
margins, and receipt of chemotherapy were not balanced be-
tween the groups, after balancing these potential confounders 
with propensity matching, the association between improved 
OS and PORT became statistically stronger. Additionally, we 
found that the patient characteristics associated with the great-
est overall survival benefit for PORT were pT4 disease, node 
positive disease, and positive surgical margins, characteristics 
which are associated with higher rates of local‐regional re-
currence in the literature.2,22,27 We observed the same trends 
in the subgroup analysis of patients with urothelial histology 
with significant improvement in overall survival with the ad-
dition of PORT in pT4 disease, node positive disease, and 
positive surgical margins. This is the first study to report an 
overall survival benefit for PORT in LABC patients and lends 
 
Univariable Multivariable
Hazard ratio P‐Value Hazard ratio P‐Value
Chemotherapy
None Reference Group  Reference Group  
Single‐agent 0.95 (0.86‐1.05) 0.338 0.74 (0.67‐0.83) <0.0001
Multi‐agent 0.78 (0.75‐0.81) <0.0001 0.69 (0.66‐0.72) <0.0001
Number of agents 
unknown
0.85 (0.76‐0.95) 0.004 0.83 (0.75‐0.92) <0.0001
T A B L E  3  (Continued)
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further support to the change in the National Comprehensive 
Cancer Network (NCCN) guidelines that added PORT as 
a treatment option to consider for patients with LABC. It 
should be noted, however, that the patients included in this 
analysis were treated prior to the NCCN guidelines incorpo-
rating PORT and it may be that patients referred for PORT in 
F I G U R E  2  Kaplan‐Meier overall survival curves in the propensity score matched cohort for PORT vs no PORT in: (A) entire matched 
cohort; (B) matched pathologic T4 (pT4) disease; (C) matched node positive disease; (D) matched positive margins; (E) matched both pT4 disease 
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this cohort had very poor prognostic factors, which would not 
be well‐captured in the NCDB (ie, grossly positive margins).
Although the strengths of our study include the large 
number of patients treated in the modern RT era, there are 
notable limitations. As an observational study, we were un-
able to control for all potential confounding factors that may 
influence the apparent survival benefit of PORT, though PS 
matching helps control for a large number of measured con-
founders. Key variables are not included in the NCDB, in-
cluding information on cause of death and recurrence as well 
as radiation treatment volumes (ie, pelvis vs cystectomy bed 
alone). Detailed information on chemotherapeutic agents (ie, 
cisplatin vs noncisplatin based) used and their dosing are also 
not available in the NCDB. There is also a possible selection 
bias with respect to treatment assignment that cannot be fully 
adjusted for on a multivariable analysis and with matching. 
Patients receiving PORT may be representative of healthier 
patients who can tolerate additional therapy, or conversely, 
may be representative of patients with particularly advanced 
disease who were referred for a nonstandard adjuvant ther-
apy. We conducted a sensitivity analysis to assess the ro-
bustness of our findings to unmeasured confounding to try 
to address these limitations. Lastly, in our study, the OS for 
patients may be worse than OS reported in clinical trials such 
as SWOG 8710 and other institutional retrospective series.1,14 
This difference may be related to inclusion of patients with 
comorbidities who would have been excluded from a clinical 
trial as well as heterogeneity in the radiation dose, treatment 
volumes, and chemotherapy administration.28,29 Importantly, 
the lack of details on chemotherapeutic regimens used in this 
study (eg, chemotherapy agent(s), number of cycles adminis-
tered, and doses) is a major limitation of the database.
To our knowledge, this is the largest study investigating 
the impact of PORT on OS in patients with LABC. Based 
on this retrospective analysis, PORT appears to be associ-
ated with improved OS and these findings lend support to 
the use of PORT. While not definitive, these results suggest 
that patients with LABC should be considered for PORT. The 
benefit for PORT appears to be particularly pronounced for 
pT4 disease, positive nodes, and/or positive margins. Phase 3 
trials of PORT for patients with LABC are warranted.
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